Electric-truck maker Nikola Motor Co. said it’s ready for the next chapter in its growth, with a March 3 announcement that it’s going public by merging with VectoIQ Acquisition Corp., a publicly traded special purpose acquisition company. ...
In January, Sorrento Therapeutics (SRNE) \-- a biotech specializing in cancer pain alleviation, but with no profits and only $25 million in trailing revenue -- rejected a $1 billion buyout offer from an unidentified private equity fund, which had valued the company's shares at "up to $7."Sorrento management said the offer "significantly undervalues the company" -- which at first glance seems a strange statement to make, given that Sorrento stock currently costs just a little more than $2 a stub, and the entire company is worth less than $400 million.But just because it's strange doesn't mean it's untrue -- which brings us to H.C. Wainwright.Wainwright analyst Raghuram Selvaraju released a note updating investors on new "Phase 1b" clinical trial results on Sorrento's lead pain management drug candidate, resiniferatoxin (RTX). Reviewing the status of 14 patients involved in the clinical study, Selvaraju observes that, so far, "no dose-limiting toxicities (DLTs) have been...